What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Preventative vaccine for Shigella protection against 4 unique serotypes”In the company’s words, NCT07205926 on ClinicalTrials.gov
- Main trialPhase 1
- “Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults”In the company’s words, NCT07205926 on ClinicalTrials.gov
Other drugs for Shigella
- S. Flexneri-S. Sonnei bivalent conjugate vaccineBeijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Phase 3
- ShigETEC liveEveliqure Biotechnologies GmbH · Phase 2
- BacteriophageIntralytix, Inc. · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 26 Jan 2026 | First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026